Parkinson’s disease Clinical Trials in the EU, 2026
The most recently authorised trials on the EU Clinical Trials Information System (CTIS), the single register for every trial run under the EU Clinical Trials Regulation (536/2014). CTIS holds a far larger historical archive than any one list can usefully show — this register states both numbers rather than picking one.
About this register
This register is built from the EU Clinical Trials Information System (CTIS), run by the European Medicines Agency: the single register for every trial authorised under the EU Clinical Trials Regulation (536/2014). CTIS held 12,594 trial records at the last sync on 10 Oct 2026, 03:17 UTC; this register shows the 2,558 most recently authorised of them, a stated recency window rather than the full archive. The list can be downloaded as CSV or JSON.
This page shows the 14 of those trials with a site in Parkinson’s disease.
How many recently authorised EU trials have a site in Parkinson’s disease?
14 of the 2,558 most recently authorised trials in this register list a site in Parkinson’s disease; 2 of them are Phase III. Trials are counted by authorisation on CTIS, not by recruitment status, which CTIS does not publish in the same form as ClinicalTrials.gov.
Summary by phase
| Phase | Trials | Share |
|---|---|---|
| Phase I | 6 | 42.9% |
| Phase II | 6 | 42.9% |
| Phase III | 2 | 14.3% |
Most active sponsors
| Lead sponsor | Trials |
|---|---|
| Tridem Bioscience FlexCo | 2 |
| Amsterdam UMC Stichting | 1 |
| Askbio Inc. | 1 |
| Gen Ilac Ve Saglik Urunleri Sanayi Ve Ticaret A.S. | 1 |
| H. Lundbeck A/S | 1 |
| Helse Bergen HF | 1 |
| Karolinska Institutet | 1 |
| Karolinska University Hospital | 1 |
| Mission Therapeutics Limited | 1 |
| Regeneron Pharmaceuticals Inc. | 1 |